Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (surpass-1): A double-blind, randomised, phase 3 trial
Notably, the disruption is not caused by the medication itself but by the body's response to decreased fat mass and improved insulin sensitivity
In vitro data demonstrated that red blood cells have a high capacity for metabolism of lisdexamfetamine
There have been several cardiovascular outcomes trials (CVOTs) involving GLP-1RAs, which have supported the overall cardiovascular benefits of these drugs
Shortens sleep onset and improves sleep quality This 200 milligram dose of theanine is the standard, and the effectiveness of this dose for improving sleep quality has been repeatedly verified by the peer-reviewed research literature
Ma T, Lu W, Wang Y, Qian P, Tian H, Gao X, et al